Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Clin Endocrinol Metab ; 99(9): 3418-26, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24905063

RESUMO

CONTEXT: Women with primary ovarian insufficiency have significantly lower serum estradiol and T levels compared with regularly menstruating women. They also have significantly reduced bone mineral density (BMD). OBJECTIVE: The objective of the study was to evaluate the efficacy of hormone replacement in maintaining BMD in these young women. DESIGN AND SETTING: This was a randomized, double-blind, single-center, placebo-controlled clinical trial at the National Institutes of Health clinical center (Bethesda, Maryland). PARTICIPANTS: Young women with primary ovarian insufficiency participated in the study. INTERVENTIONS: We compared the effect of estradiol and progestin replacement (n = 72) vs estradiol, progestin, and T replacement (n = 73) on BMD. We also compared findings with a contemporaneous control group of normal women (n = 70). All patients received transdermal estradiol (100 µg/d) plus oral medroxyprogesterone acetate 10 mg/d (12 d/mo) for a 3-month run-in period before being randomized in a double-blinded fashion to the addition of transdermal T (150 µg/d) or placebo. MAIN OUTCOME MEASURE: Change in BMD at the femoral neck was measured by dual-energy x-ray absorptiometry. RESULTS: At screening, patients had significantly lower femoral neck BMD compared with control women (0.77 vs 0.81 g/cm(2), P = .001) and did not differ in body mass index, age at menarche, or education level. Normal control women lost femoral neck BMD over the study period, whereas patients on estradiol and progestin therapy gained BMD; and at the end of the study period, femoral neck BMD of patients on estradiol and progestin therapy did not differ from that of control women (0.80 g/cm(2) in both groups, P = .9). The addition of T showed no further benefit (percentage change in BMD 3.9 vs 2.4, respectively, P = .9). Nonetheless, using a repeated-measures model, the T group achieved a mean BMD in the femoral neck 0.015 g/cm(2) higher than the placebo group at 3 years (95% confidence interval -0.005 to 0.034, P = .13). Similar findings were observed in the lumbar spine BMD as well. CONCLUSION: Long-term physiological transdermal estradiol replacement in combination with oral medroxyprogesterone acetate restores mean femoral neck BMD to normal in young women with spontaneous 46,XX primary ovarian insufficiency. However, the addition of physiological transdermal T replacement did not provide additional benefit.


Assuntos
Densidade Óssea/efeitos dos fármacos , Estradiol/administração & dosagem , Terapia de Reposição Hormonal/métodos , Insuficiência Ovariana Primária/tratamento farmacológico , Insuficiência Ovariana Primária/metabolismo , Testosterona/administração & dosagem , Transtornos 46, XX do Desenvolvimento Sexual/tratamento farmacológico , Transtornos 46, XX do Desenvolvimento Sexual/metabolismo , Absorciometria de Fóton , Administração Cutânea , Adulto , Anticoncepcionais Femininos/administração & dosagem , Método Duplo-Cego , Quimioterapia Combinada , Estradiol/sangue , Feminino , Colo do Fêmur/diagnóstico por imagem , Colo do Fêmur/metabolismo , Humanos , Acetato de Medroxiprogesterona/administração & dosagem , Estudos Prospectivos , Testosterona/sangue , Terapêutica , Adulto Jovem
2.
Menopause ; 21(9): 952-61, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24473536

RESUMO

OBJECTIVE: Women with primary ovarian insufficiency (POI) display low androgen levels, which could contribute to mood and behavioral symptoms observed in this condition. We examined the effects of physiologic testosterone therapy added to standard estrogen/progestin therapy on quality of life, self-esteem, and mood in women with POI. METHODS: One hundred twenty-eight women with 46,XX spontaneous POI participated in a 12-month randomized, placebo-controlled, parallel-design investigation of the efficacy of testosterone augmentation of estrogen/progestin therapy. Quality of life, self-esteem, and mood symptoms were evaluated with standardized rating scales and a structured clinical interview. Differences in outcome measures between the testosterone and placebo treatments were analyzed by Wilcoxon rank sum tests. RESULTS: No differences in baseline characteristics, including serum hormone levels (P > 0.05), were found. Baseline mean (SD) Center for Epidemiologic Studies Depression Scale scores were 10.7 (8.6) and 9.2 (7.8) for testosterone and placebo, respectively (P = 0.35). After 12 months of treatment, measures of quality of life, self-esteem, and mood symptoms did not differ between treatment groups. Serum testosterone levels achieved physiologic levels in the testosterone group and were significantly higher compared with placebo (P < 0.001). Baseline testosterone levels were not associated with either adverse or beneficial clinical effects. CONCLUSIONS: A 150-µg testosterone patch achieves physiologic hormone levels in women with POI. Our findings suggest that augmentation of standard estrogen/progestin therapy with physiologic testosterone therapy in young women with POI neither aggravates nor improves baseline reports of quality of life or self-esteem and had minimal effects on mood. Other mechanisms might play a role in the altered mood accompanying this disorder.


Assuntos
Insuficiência Ovariana Primária/sangue , Qualidade de Vida , Testosterona/administração & dosagem , Administração Cutânea , Adolescente , Adulto , Método Duplo-Cego , Feminino , Terapia de Reposição Hormonal , Humanos , Menopausa , Transtornos do Humor , Insuficiência Ovariana Primária/psicologia , Psicometria , Autoimagem , Testosterona/sangue , Resultado do Tratamento
3.
Fertil Steril ; 93(7): 2321-9, 2010 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-19243752

RESUMO

OBJECTIVE: To examine factors associated with emotional well-being in women with spontaneous primary ovarian insufficiency. DESIGN: Cross-sectional and case-control study. SETTING: Clinical research center, national U.S. health research facility. PATIENT(S): Women diagnosed with spontaneous 46,XX primary ovarian insufficiency (n = 100) at a mean age of 32.4 years and healthy control women of similar age (n = 60). INTERVENTION(S): Administration of validated self-reporting instruments. MAIN OUTCOME MEASURE(S): Illness uncertainty, stigma, goal disengagement/re-engagement, purpose in life, Positive and Negative Affect Schedule, Center of Epidemiologic Studies Depression Scale, State-Trait Anxiety Inventory. RESULT(S): Compared with controls, women with spontaneous primary ovarian insufficiency scored adversely on all measures of affect. Illness uncertainty and purpose in life were significant independent factors associated with anxiety (R(2) = 0.47), stigma and purpose in life were the significant independent factors associated with depression (R(2) = 0.51), and goal re-engagement and purpose in life were significantly and independently associated with positive affect (R(2) = 0.43). CONCLUSION(S): This evidence supports the need for prospective studies. Our findings are consistent with the hypothesis that clinicians could improve the emotional well-being of their patients with primary ovarian insufficiency by [1] informing them better about their condition, [2] helping them to feel less stigmatized by the disorder, and [3] assisting them in developing alternative goals with regard to family planning as well as other goals.


Assuntos
Adaptação Psicológica/fisiologia , Efeitos Psicossociais da Doença , Objetivos , Saúde Mental , Preconceito , Insuficiência Ovariana Primária/etiologia , Estresse Psicológico/complicações , Adulto , Estudos de Casos e Controles , Cromossomos Humanos X , Emoções , Feminino , Humanos , Estilo de Vida , Inventário de Personalidade , Insuficiência Ovariana Primária/epidemiologia , Insuficiência Ovariana Primária/psicologia , Qualidade de Vida , Fatores de Risco , Autoimagem , Estresse Psicológico/fisiopatologia , Incerteza
4.
J Clin Endocrinol Metab ; 94(7): 2277-83, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19401379

RESUMO

CONTEXT: Osteoporosis primarily affects postmenopausal women. However, young women with estrogen deficiency also are at increased risk for low bone density. OBJECTIVE: The aim of the study was to assess bone density and associated risk factors for reduced bone density in young, estrogen-deficient women using primary ovarian insufficiency (POI) as the disease model. DESIGN AND SETTING: We conducted a cross-sectional study at a tertiary care research center. PARTICIPANTS: We studied women with POI (n = 442), concurrent controls (n = 70), and matched controls from NHANES III (n = 353). PRIMARY OUTCOME MEASURE: We measured bone mineral density (BMD) using dual-energy x-ray absorptiometry. RESULTS: Patients on average had 2-3% lower BMD at L1-L4, femoral neck, and total hip (P < 0.01 at all sites). The modifiable risk factors for BMD below the expected range for age (Z-score <-2) were: more than 1-yr delay in diagnosis of estrogen deficiency (P = 0.018), low (<32 ng/ml) vitamin D levels (P = 0.002), estrogen replacement nonadherence (P = 0.002), low calcium intake (P = 0.005), and lack of exercise (P = 0.005). As compared to Caucasians, African-American and Asian women with POI were 3.18 and 4.34 times more likely, respectively, to have Z-scores below -2 (P = < 0.0001 for both). Race was an overall risk factor, but on regression modeling, not an independent predictor of low bone density. CONCLUSIONS: Women with POI have lower bone density compared to regularly menstruating women. Compared to Caucasians, minority women with estrogen deficiency are more likely to have BMD below the expected range for age. This racial disparity appears to be related to a combined effect of several modifiable risk factors. Delay in diagnosis of POI also contributes to reduced bone density by delaying proper therapy.


Assuntos
Densidade Óssea , Estrogênios/deficiência , Hipogonadismo/fisiopatologia , Adulto , Densidade Óssea/fisiologia , Estudos de Casos e Controles , Estudos Transversais , Feminino , Colo do Fêmur/diagnóstico por imagem , Quadril/diagnóstico por imagem , Humanos , Hipogonadismo/complicações , Hipogonadismo/diagnóstico por imagem , Hipogonadismo/etnologia , Região Lombossacral/diagnóstico por imagem , Osteoporose/diagnóstico por imagem , Osteoporose/epidemiologia , Osteoporose/etnologia , Osteoporose/etiologia , Doenças Ovarianas/complicações , Doenças Ovarianas/etiologia , Doenças Ovarianas/fisiopatologia , Radiografia , Fatores de Risco , Adulto Jovem
5.
South Med J ; 101(11): 1177-9, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19088537

RESUMO

A 75-year-old male presented with shortness of breath and abdominal pain; he had undergone coronary artery bypass graft surgery three months ago and had a history of coronary artery disease, hypertension, and end-stage renal disease. Transthoracic echocardiogram showed a right atrial mass. A computed axial tomography scan showed an atrial mass and type A aortic dissection. The patient sustained cardiorespiratory arrest and died. An autopsy showed an 8 cm atrial intramural hematoma originating from a dissecting aneurysm. This is the first case of right atrial intramural hematoma associated with aortic dissection exhibiting high mortality. Early diagnosis using multiple imaging modalities including magnetic resonance imaging and timely surgical intervention may improve survival. Intramural hematomas should be considered in patients presenting with right-sided cardiac lesions.


Assuntos
Doenças da Aorta/complicações , Cardiomiopatias/complicações , Hematoma/complicações , Idoso , Doenças da Aorta/diagnóstico , Doenças da Aorta/fisiopatologia , Cardiomiopatias/diagnóstico , Evolução Fatal , Humanos , Masculino
6.
Ann N Y Acad Sci ; 1135: 43-51, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18574207

RESUMO

Menstruation is the cyclic, orderly sloughing of the uterine lining on account of the interactions of hormones produced by the hypothalamus, pituitary, and ovaries. There is a tendency among parents and clinicians to view oligo-amenorrhea as a normal variant in the teen years. In fact, the 95th percentile for the time interval between cycles is 90 days. Thus, it is abnormal for an adolescent to be amenorrheic for greater than 3 months, even in the early gynecologic years. Identification of abnormal menstrual patterns throughout adolescence may permit early identification of potential health concerns for adulthood. Few problems in gynecologic endocrinology are as complex or challenging to the clinician as amenorrhea. However, thorough evaluation of menstrual cycle disorders in adolescence provides a window of opportunity for early diagnosis and treatment of conditions affecting the hypothalamic-pituitary-ovarian (HPO) axis. Here we discuss a systematic approach to the evaluation and treatment of amenorrhea in adolescents who do not have androgen excess. There is strong evidence that estrogen deficiency is a risk factor for later development of osteoporosis and hip fracture. Delay in the evaluation and treatment of disordered menses in some cases may contribute to reduced bone density. Both patients and clinicians need to view the ovary as an important endocrine organ that helps maintain health, especially bone health.


Assuntos
Amenorreia/diagnóstico , Amenorreia/tratamento farmacológico , Saúde , Ciclo Menstrual , Adolescente , Amenorreia/etiologia , Biomarcadores , Densidade Óssea , Estrogênios/deficiência , Feminino , Terapia de Reposição Hormonal , Humanos , Sistema Hipotálamo-Hipofisário/fisiologia , Sistema Hipotálamo-Hipofisário/fisiopatologia , Ovário/fisiologia , Ovário/fisiopatologia , Fatores de Risco
7.
Fertil Steril ; 89(2): 429-33, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17509587

RESUMO

OBJECTIVE: To determine the proportion of women with primary ovarian insufficiency who achieve normal serum LH levels on transdermal E(2) therapy. DESIGN: Prospective. SETTING: Clinical research center at a national US health research facility. PATIENT(S): Women with spontaneous primary ovarian insufficiency (n = 137) and 70 regularly menstruating control women (n = 70). INTERVENTION(S): Blood sampled from controls in the midfollicular phase and from patients while they were off E(2) for 2 weeks, then again 3 months later during the E(2)-only phase of hormone therapy (E(2) patch [100 microg/d] and oral medroxyprogesterone acetate [10 mg for 12 d/mo]). MAIN OUTCOME MEASURE(S): Serum LH. RESULT(S): While on transdermal E(2) therapy, significantly more women (51.1%, 70/137; 95% confidence interval, 42%, 60%) had serum LH levels in the normal range (5/137, 3.9% at baseline). Mean (SD) serum E(2) level significantly increased on therapy to 95.4 (84.9) pg/mL. CONCLUSION(S): A regimen of 100 microg/d of transdermal E(2) therapy achieves normal serum LH levels in approximately one half of women with spontaneous primary ovarian insufficiency. Theoretically, by avoiding inappropriate luteinization, physiologic E(2) therapy may improve follicle function in these women. Controlled studies to assess the effect of transdermal E(2) therapy on follicle function in these women are warranted.


Assuntos
Estradiol/administração & dosagem , Hormônio Luteinizante/sangue , Insuficiência Ovariana Primária/sangue , Insuficiência Ovariana Primária/tratamento farmacológico , Administração Cutânea , Adolescente , Adulto , Cromossomos Humanos X , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Genótipo , Humanos , Menopausa Precoce/sangue , Menopausa Precoce/efeitos dos fármacos , Insuficiência Ovariana Primária/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA